[Studies on immunotherapy of uterine cervical cancer by administration of schizophyllan (SPG) (author's transl)].
This study was designed to investigate effects of immunopotentiator on cervical cancer. We administered schizophyllan (SPG) as immunopotentiator to patients of cervical cancer therapy with irradiation, and examined successively immunological parameters such as blastformation of lymphocytes, skin reaction of PPD, lymphocyte counts, concentration of serum immunoglobulins, and other clinical inspections. Moreover we examined ability of interferon induction of SPG. We also calculated and compared 3 year relative survival rate of the cases administered SPG and historical controls therapy with only irradiation. In patients administered SPG the results revealed: 1) an enhancement of stimulation index of lymphocytes blastformation with PHA, 2) an enlargement of skin reaction to PPD, 3) no effects to number of lymphocytes, serum immunoglobulins, liver function and renal function, 4) an interferon activity on patients' sera of cervical cancer after administration of SPG, and 5) patients administrated SPG had significantly high relative survival rate in comparison with the historical control of cervical cancer cases treated solely by irradiation.
D000368:Aged; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D007369:Interferon Inducers / Q000032:analysis; D008213:Lymphocyte Activation / Q000187:drug effects; D008212:Lymphocyte Depletion; D008875:Middle Aged; D012566:Sizofiran / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*
D006025:Glycosaminoglycans; D007369:Interferon Inducers; D012566:Sizofiran